RxDoctor Payments Data

Guido Sclabas, MD

Surgery · Tulsa, OKNPI 1790832517

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (40.1%), travel and lodging and other — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 86.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $5,447 and has fallen 82.0% since, to $983 in 2025.

$13,080in general payments, 2019–2025

Across 58 payments — averaging $225.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$11K
  • Histosonics, Inc.$983
  • Medical Device Business Services, Inc.$630
  • TELA Bio, Inc.$85
  • Angiodynamics, Inc.$55
  • Nestle Healthcare Nutrition Inc.$36
  • plus $39 from 2 others

What the payments were for

  • Consulting fees$711%
  • Travel & lodging$3,61628%
  • Food & beverage$1,1449%
  • Education$5,25040%
  • Other$3,00023%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,080 in reported general payments places this provider in the 85th percentile of 290 surgery providers in Oklahoma.

See all surgery providers in Oklahoma

Medicare billing

Part B allowed, 2024
$167,976
Medicare patients
263
Services billed
653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide12$571,817
CreonLipase/Protease/Amylase15$46,258
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen69$393
Pantoprazole Sodium30$257
Ondansetron Hcl22$117
Tramadol Hcl15$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$23$571,81712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 290 surgery providers in Oklahoma.

Other surgery in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →